HBV Mutation Detail Information

> M204V Search Result


Mutation Information
Mutation Site M204V
Mutation Type Amino acid level
Gene/Protein/Region Type RT
Genotype/Subtype B
Country China
Literature Information
PubMed PMID 21442057
Disease Chronic hepatitis B
Published Year 2010
Journal Hepatology international
Title Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation.
Author Peng CY,Chen CB,Lai HC,Su WP,Chuang PH,Wu HD,Jeng LB
Evidence Compared to compensated patients, decompensated patients achieved a higher rate of HBeAg loss (25.8 vs. 14.3%; P = 0.0805) at 3 months of therapy, a higher rate of serum HBV DNA negativity (53.2 vs. 29.8%; P = 0.0042), and a lower rate of rtM204V/I mutation (3.2 vs. 16.7%; P = 0.0139) after 12 months of lamivudine therapy.

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation